Premium
CD34+ megakaryocytes (≥30%) are associated with megaloblastic anaemia and non‐acute myeloid neoplasia
Author(s) -
InsuastiBeltran Giovanni,
Steidler Nichole L,
Kang Huining,
Reichard Kaaren K
Publication year - 2012
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/j.1365-2559.2012.04259.x
Subject(s) - myeloid , cd34 , medicine , myelodysplastic syndromes , neoplastic transformation , pathology , neoplastic cell , bone marrow , cancer , biology , stem cell , cell , carcinogenesis , genetics
Insuasti‐Beltran G, Steidler N L, Kang H & Reichard K K
(2012) Histopathology 61, 694–701 CD34+ megakaryocytes (≥30%) are associated with megaloblastic anaemia and non‐acute myeloid neoplasia Aims: To evaluate the sensitivity and specificity of CD34 staining of megakaryocytes (MKs), in order to distinguish non‐neoplastic and neoplastic bone marrows (BMs). Methods and results: Three hundred BMs (120 non‐neoplastic and 180 neoplastic) were evaluated for percentage and intensity of CD34 staining of MKs. The selected non‐neoplastic cases included anaemia, autoimmune conditions, immune thrombocytopenia (ITP), and staging BMs. The neoplastic cases included myelodysplastic syndromes and/or myeloproliferative neoplasms (MDS, MPN, MDS/MPN). Eight per cent of non‐neoplastic (9/120) cases and 13% of neoplastic (24/180) cases showed ≥30% CD34+ MKs, and these were essentially restricted to cases of megaloblastic anaemia (MBA) and non‐acute myeloid neoplasms. The finding of ≥30% CD34+ MKs did not distinguish between categories of non‐acute myeloid neoplasms. MDS cases with ≥30% CD34+ MKs had lower platelet counts than cases with <30% ( P = 0.03). Conclusions: In complex BM cases, the presence of ≥30% CD34+ MKs constitutes a potentially useful diagnostic tool with which to distinguish non‐acute myeloid neoplasms and MBA from non‐MBA reactive conditions, for minimal additional cost.